Reuters Health Report

If you are having trouble viewing this email or would like to view it in your web browser, CLICK HERE

Good Morning Postlinuxeg, MON 14 Jun 2010 
 
Senator urges release of sunscreen chemical data
Key cuts to healthcare waste saves $3.6 trillion
Defect risk higher for assisted fertility babies
Common blood pressure drugs may raise cancer risk
Documents show J&J bought Motrin before recall
Scientists find genes linked to testicular cancer
Drugmakers to share data to speed brain research
Birth complications more common at night
Slightly preterm, healthy babies do OK later on
U.S. court grants injunction against Dr Reddy's

Senator urges release of sunscreen chemical data
June 13, 2010 05:11 PM ET
NEW YORK (Reuters) - A senator on Sunday called on the FDA to reveal findings on a possible link between a chemical found in most sunscreens and skin cancer.

Full Article
Key cuts to healthcare waste saves $3.6 trillion
June 14, 2010 12:01 AM ET
WASHINGTON (Reuters) - The U.S. healthcare industry can cut $3.6 trillion in waste over 10 years with a few common-sense steps to eliminate fraud, errors and to encourage efficiency and healthier behavior, according to an analysis by Thomson Reuters.

Full Article
Defect risk higher for assisted fertility babies
June 13, 2010 07:38 AM ET
LONDON (Reuters) - Babies born to couples who had fertility treatment have a greater risk of birth abnormalities and doctors should be prepared to warn potential parents about these risks, French scientists said on Sunday.

Full Article
Common blood pressure drugs may raise cancer risk
June 13, 2010 02:09 PM ET
CHICAGO (Reuters) - A widely used class of blood pressure drugs may slightly increase the risk of cancer, U.S. researchers said on Sunday, and they are calling on U.S. regulators to take a closer look.

Full Article
Documents show J&J bought Motrin before recall
June 11, 2010 07:10 PM ET
NEW YORK (Reuters) - Johnson & Johnson planned to remove potentially flawed lots of its Motrin over-the-counter pain reliever from store shelves by having contractors buy stocks of it, documents obtained by Reuters show.

Full Article
Scientists find genes linked to testicular cancer
June 13, 2010 01:08 PM ET
LONDON (Reuters) - British scientists have found three new genetic risk factors for testicular cancer, the most common form of the disease in young men, and say their findings should aid efforts for better treatments and earlier diagnosis.

Full Article
Drugmakers to share data to speed brain research
June 11, 2010 05:43 PM ET
WASHINGTON (Reuters) - Major drugmakers will share data from their clinical trials for Alzheimer's and Parkinson's disease in an effort to speed the development of new medicines to treat the brain disorders.

Full Article
Birth complications more common at night
June 11, 2010 03:23 PM ET
NEW YORK (Reuters Health) - Picking the time of day to give birth may not be a choice very many women can make, but it could influence her chances of a smooth delivery, new research shows.

Full Article
Slightly preterm, healthy babies do OK later on
June 11, 2010 05:22 PM ET
NEW YORK (Reuters Health) - If babies are born a couple of weeks early, but are healthy, they're not at greater risk of developmental or behavior problems later on, new research shows.

Full Article
U.S. court grants injunction against Dr Reddy's
June 13, 2010 11:28 PM ET
NEW DELHI (Reuters) - Indian drugmaker Dr. Reddy's Laboratories said a U.S. court has granted a preliminary injunction against the company from distributing a generic version of allergy drug Allegra-D.

Full Article
 
 











REUTERS www.reuters.com
Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book.Details
Subscribe to other Reuters newsletters
Unsubscribe from this newsletter.


Forward to a friend Send this mailing to a friend or colleague


Reuters.com: Help and Contact Us | Advertise With Us | Mobile | Newsletters | RSS RSS Feed | Interactive TV | Labs | Reuters in Second Life | Archive | Site Index | Video Index

Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers

0 comentários: